MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$10,054M
Net Income
$2,375M
Net Profit Margin
23.62%
EPS
$4.37
Unit: Million (M) dollars
Revenue Breakdown
Other Products
Repathaevolocumab
Prolia
Others
Revenue Breakdown
US
Non Us
Product And Service Other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
10,054
8,618
9,866
9,557
Cost of sales
2,811
2,744
2,976
3,082
Research and development
1,868
1,719
2,142
1,900
Selling, general and administrative
1,745
1,602
1,952
1,720
Other
116
-113
76
329
Total operating expenses
6,540
5,952
7,146
7,031
Operating income
3,514
2,666
2,720
2,526
Interest expense, net
673
657
653
685
Other (expense) income, net
-73
75
-553
2,080
Income before income taxes
2,768
2,084
1,514
3,921
Provision for income taxes
393
265
181
705
Net income
2,375
1,819
1,333
3,216
Basic EPS
4.4
3.37
2.478
5.98
Diluted EPS
4.37
3.34
2.45
5.93
Basic Average Shares
540,000,000
540,000,000
538,000,000
538,000,000
Diluted Average Shares
544,000,000
544,000,000
544,000,000
542,000,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
US
$1,283M
(4.39%↑ Y/Y)
Non Us
$414M
(-10.20%↓ Y/Y)
US
$510M
(41.27%↑ Y/Y)
Non Us
$443M
(32.24%↑ Y/Y)
US
$478M
(-35.84%↓ Y/Y)
Non Us
$281M
(-25.46%↓ Y/Y)
US
$550M
(39.24%↑ Y/Y)
Non Us
$164M
(33.33%↑ Y/Y)
US
$574M
(-3.85%↓ Y/Y)
Non Us
$6M
(-14.29%↓ Y/Y)
US
$520M
(11.59%↑ Y/Y)
Non Us
$56M
(43.59%↑ Y/Y)
US
$431M
(-15.82%↓ Y/Y)
Non Us
$60M
(-43.40%↓ Y/Y)
Revenue From Contract
With Customer...
$486M
(42.11%↑ Y/Y)
US
$285M
(5.56%↑ Y/Y)
Non Us
$187M
(64.04%↑ Y/Y)
US
$275M
(20.61%↑ Y/Y)
Non Us
$155M
(9.93%↑ Y/Y)
US
$399M
(14.33%↑ Y/Y)
Non Us
$1M
(-99.78%↓ Y/Y)
Non Us
$258M
(2.38%↑ Y/Y)
US
$94M
(-12.15%↓ Y/Y)
US
$187M
(-46.11%↓ Y/Y)
Non Us
$165M
(-10.81%↓ Y/Y)
Non Us
$171M
(6.21%↑ Y/Y)
US
$167M
(15.97%↑ Y/Y)
US
$317M
(-74.21%↓ Y/Y)
Non Us
$18M
(-96.10%↓ Y/Y)
US
$201M
(-13.36%↓ Y/Y)
Non Us
$113M
(-22.60%↓ Y/Y)
US
$233M
(-81.04%↓ Y/Y)
Non Us
$55M
(-88.07%↓ Y/Y)
Other Products
$1,697M
(0.41%↑ Y/Y)
Repathaevolocumab
$953M
(36.93%↑ Y/Y)
Prolia
$759M
(-32.35%↓ Y/Y)
EVENITY
$714M
(37.84%↑ Y/Y)
Enbrel
$580M
(-3.97%↓ Y/Y)
TEPEZZA
$576M
(14.06%↑ Y/Y)
Otezla
$491M
(-20.55%↓ Y/Y)
TEZSPIRE
$486M
(42.11%↑ Y/Y)
BLINCYTO
$472M
(22.92%↑ Y/Y)
Nplate
$430M
(16.53%↑ Y/Y)
KRYSTEXXA
$400M
(14.61%↑ Y/Y)
Aranesp
$352M
(-1.95%↓ Y/Y)
Xgeva
$352M
(-33.83%↓ Y/Y)
Vectibix
$338M
(10.82%↑ Y/Y)
UPLIZNA
$335M
Kyprolis
$314M
(-16.93%↓ Y/Y)
IMDELLTRAIMDYLLTRA
$288M
Product
$9,537M
(8.73%↑ Y/Y)
Product And Service
Other
$517M
(26.72%↑ Y/Y)
Total revenues
$10,054M
(9.53%↑ Y/Y)
Operating income
$3,514M
(32.30%↑ Y/Y)
Total operating
expenses
$6,540M
(0.26%↑ Y/Y)
Income before income
taxes
$2,768M
(76.53%↑ Y/Y)
Interest expense, net
$673M
(-3.03%↓ Y/Y)
Other (expense)
income, net
-$73M
(81.47%↑ Y/Y)
Cost of sales
$2,811M
(-6.64%↓ Y/Y)
Research and development
$1,868M
(7.11%↑ Y/Y)
Selling, general and
administrative
$1,745M
(3.19%↑ Y/Y)
Other
$116M
(50.65%↑ Y/Y)
Net income
$2,375M
(65.85%↑ Y/Y)
Provision for income taxes
$393M
(188.97%↑ Y/Y)
Buy us a coffee
amgen-blue-svg
AMGEN INC (AMGN)
amgen-blue-svg
AMGEN INC (AMGN)